Navigation Links
Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
Date:8/21/2008

A has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. For more information about the Company, please visit http://www.catalystpharma.com.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including the Company's ability to successfully complete those clinical trials required for it to file a new drug application for CPP-109, the Company's ability to complete such trials on a timely basis within the budgets established for such trials, the Company's ability to protect its intellectual property and those other factors described in the Company's Annual Report on Form 10-K for 2007 and the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 that the Company has filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.


'/>"/>
SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
2. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
3. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
4. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
5. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
6. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
7. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
10. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
11. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Research and Markets has announced the addition ... Reagent, by Application - Global Forecast to 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are pharmaceutical products isolated ... most important and widely used techniques for biopharmaceutical production. ... cell culture market in 2013. Growth in the biopharmaceutical ...
(Date:7/22/2014)... According to a new ... (Technology Types - Near infrared (NIR) spectroscopy, Raman spectroscopy and ... Size, Share, Growth, Trends and Forecast, 2013 - 2019," the ... is expected to grow at a CAGR of 7.4% from ... was the largest contributor to global process spectroscopy market ...
(Date:7/22/2014)... 2014 BiologicTx ® today announced their ... Kidney Paired Donation transplant exchange utilizing BiologicTx,s proprietary matching ... 9 at the Miami Transplant Institute, located at Jackson ... Kidney Paired Donation (KPD) is an ... kidney transplant with one another due to incompatible blood ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3
... July 12, 2011 Sevocity, the leader in ... v11.1 has achieved full certification through the Certification ... a CCHIT Certified® 2011 Ambulatory EHR.  Sevocity v11.1 ... the highest level awarded by CCHIT.  The Certification ...
... 12, 2011 ,   ... are,pleased to announce that they have been engaged ... apricitabine (ATC), a late-stage,novel treatment for HIV infection. ... the,healthcare and investment business sectors. Dr ...
Cached Medicine Technology:Sevocity Division of Conceptual MindWorks Inc.'s Sevocity EHR Earns CCHIT 2011 Certification 2PharmaVentures Engaged by Avexa to Assist in the Out-licensing of Apricitabine 2
(Date:7/22/2014)... July 22, 2014 SIMpalm, ... updated payment app for Forte Payment System. Forte Mobile ... ACH payments on iPhone, iPod and iPad. The ... been recently updated by SIMpalm. This update was for ... currently supported on iOS 4.3 and is available to ...
(Date:7/22/2014)... treatment and cardiovascular risk assessment state that men have ... cardiovascular disease or of having a heart attack or ... (based on age, smoking history, and cholesterol and blood ... and how aggressively to treat high cholesterol are examined ... , a peer-reviewed publication from Mary Ann Liebert, Inc., ...
(Date:7/22/2014)... July 22, 2014 The Beryl Institute ... third annual Institute Scholar Program. These offerings reinforce the ... patient experience in healthcare and the need for rigorous ... grant and scholar programs are intended to ... Value of focusing on the patient experience before, ...
(Date:7/22/2014)... NY (PRWEB) July 22, 2014 ... ( http://www.risperdallawsuitcenter.com/ ) in the Philadelphia ... to deny punitive damages in cases alleging the ... growth), Bernstein Liebhard LLP reports. In an Order ... denied a plaintiffs’ request to certify the matter ...
(Date:7/22/2014)... 22, 2014 The park is the ... Kendalltown Homeowners Association, Inc., made a recent ... community with the purchase of playground equipment from American ... in beautiful Miami Florida, and is a 475-unit community ... the surrounding landscape has created a tropical paradise with ...
Breaking Medicine News(10 mins):Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3
... cancer drugs had yesterday won the final draft of approval ... ,The National Institute for Health and Clinical Excellence ... the use of three types of aromatase inhibitors in postmenopausal ... drugs would act by reducing the risk of tumors spreading ...
... is for hiking and camping, but it brings with it ... In order to prevent such illnesses, researchers //are looking at ... tea and vitamins C and E in preventing infection by ... Infectious Disease, part of the National Institutes of Health, awarded ...
... The central government will send an advisory to all ... aerated soft drinks //after an independent report found heavy ... an advisory to all state governments to educate the ... aerated soft drinks," Health Minister Anbumani Ramadoss told reporters ...
... study to be published in the August 15 issue of ... The Heart Research Institute in Sydney have warned// that a ... of burger can be sufficient enough to cause heart attack. ... 18 and 40, the researchers were shocked to find that ...
... Chairman, Eddie Thompson, who was diagnosed with prostate cancer ... for the disease at Ninewells Hospital. ,In a ... behalf last night, details of his illness were released ... media about his health. ,The new ...
... out some alarming statistics regarding the HIV and AIDS status ... ,Dr. Sheela Basrur, Ontario's chief medical officer, said, ... living with HIV and AIDS has increased in part because ... the mortality rates have been reduced through the introduction of ...
Cached Medicine News:Health News:Antioxidants Could Halt Rocky Mountain Spotted Fever 2
... The Answer to Micro-Incision Cataract ... Technology With its unique double-step ... knife is ideal for MICS. ... reproducible incisions that allow you ...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: